Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery

June 7, 2011 updated by: IOPtima Ltd.
The aim of the study is to evaluate the safety and effectiveness of the IOPtiMate (OT-135P) in Laser Assisted Non-Penetrating Glaucoma surgery in Open-Angle and Pseudoexfoliative Glaucoma patients.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kfar-Saba, Israel
        • Ophthalmology ward, Meir Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patient must be 18 years of age or older.
  2. Patient must have primary open angle glaucoma or pseudo-exfoliative glaucoma in the study eye; diagnosis is based on glaucomatous optic neuropathy, Shaffer angle of +2 and visual field defect attributed to glaucoma (at least two consecutive abnormal visual field test results, defined as a pattern SD (PSD) outside the 95% normal confidence limits and/or glaucoma Hemifield Test (Carl Zeiss Meditec, Inc.).
  3. Eye to be treated must be phakic or pseudophakic eye with no ocular disorder or ocular diseases but cataract, and no prior surgical intervention in study eye but cataract surgery with clear corneal incision and trabeculoplasty performed > 3 months ago.
  4. Patient is indicated for filtration surgery.
  5. Presence of ocular hypertension, defined as an intraocular corrected pressure (IOP) ≥ 21 mm Hg in the study eye, while on maximal tolerated medications . This IOP level of above or equal 21 mmHg must be verified and recorded in the most recent 2 consecutive measurements (but not taken on the same day) prior to operation.
  6. Best corrected visual acuity (BCVA) better than 20/200 in the fellow eye.
  7. Optic neuropathy is attributed exclusively to glaucoma.
  8. Patient or legal guardian agrees to sign written informed consent prior to study participation.
  9. Patient is able and willing to complete post-operative follow-up requirements.

Exclusion Criteria:

  1. Patient has previously undergone a non-penetrating glaucoma surgery with the IOPtima CO2 Laser System in fellow eye.
  2. Diagnosis of glaucoma other than primary open angle glaucoma or pseudo-exfoliative glaucoma.
  3. History of previous intraocular surgery in the study eye; referring to but not limited to glaucoma filtering surgery (penetrating and non-penetrating), laser gonioplasty, corneal transplant, and history of any other laser ocular procedures except for laser trabeculoplasty surgery.
  4. Laser trabeculoplasty surgery within the last three months in the study eye.
  5. Study eye is aphakic.
  6. Patients with previous cataract extraction with scleral tunnel and or conjunctival incision in the study eye.
  7. Proliferative or severe non-proliferative retinopathy in either eye.
  8. Eyes with (dilated) pupil diameter of less than 2 mm in the study eye.
  9. Discernable congenital anomaly of the anterior chamber angle in the study eye.
  10. Patients with neuropathy other than glaucoma in the study eye.
  11. Patient with RVO (retinal vein occlusion) in the study eye.
  12. Patient with RAO (retinal artery occlusion) in the study eye.
  13. History of prior vitrectomy or Vitreous Hemorrhage (VH) in the study eye.
  14. Patient with media opacification which may interfere with optic nerve evaluation in the study eye.
  15. Patient with a history of severe eye trauma in the study eye
  16. Patient with ocular malformations such as microphthalmia in the study eye.
  17. Patient with concurrent inflammatory / infective eye disorder (e.g. episcleritis, scleritis) in the study eye
  18. Patient with any sign of past or present uveitis (anterior / posterior)
  19. Patient with known allergy to the study medications.
  20. Patient with severe systemic disease or disabling conditions such as: chronic renal failure requiring dialysis, severe and disenabling neurological disease, and post organ transplants.
  21. Patient participating in another clinical trial or participation in another clinical trial is < 3 months.
  22. Patient is pregnant or breast feeding. Women of child bearing age will submit a urine sample result for β-HCG (Pregnancy test) within 2 weeks of surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: IOPtiMate
patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Intra-Ocular Pressure (IOP)
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of anti-Glaucoma Medications
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Noa Geffen, Dr., Glaucoma service, Ophthalmology ward, Meir Hospital, Kfar-Saba
  • Principal Investigator: Shlomo Melamed, Dr., Glaucoma service, Ophthalmology ward, Sheba Hospital, Tel-Hashomer Israel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2010

Primary Completion (ANTICIPATED)

February 1, 2012

Study Completion (ANTICIPATED)

February 1, 2012

Study Registration Dates

First Submitted

January 28, 2010

First Submitted That Met QC Criteria

January 28, 2010

First Posted (ESTIMATE)

January 29, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

June 8, 2011

Last Update Submitted That Met QC Criteria

June 7, 2011

Last Verified

June 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

  • PCL-34-003 (03)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Open Angle Glaucoma

Clinical Trials on Laser Assisted Non-penetrating glaucoma surgery

Subscribe